Open access. Antipsychotics are the drugs prescribed to treat psychotic disorders; however, patients often fail to adhere to their treatment, and this has a severe negative effect on prognosis in these kinds of illnesses. Among the wide range of risk factors for treatment nonadherence, this systematic review covers those that are most important from the point of view of clinicians and patients and proposes guidelines for addressing them.
Prolactin-related adverse effects contribute to nonadherence and adverse health consequences, particularly in women with severe mental illness. Treating these adverse effects may improve treatment acceptability, adherence, and long-term outcomes.. MPFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Altered connectivity of dorsolateral prefrontal cortex (DLPFC) and hippocampus during working memory is considered an intermediate phenotype for schizophrenia (SCZ), but the relevance for other mental disorders with shared genetic background remains unknown. Here we investigated its presence in unaffected first-degree relatives of patients with bipolar disorder (BD) or major depressive disorder (MDD). Furthermore, we aimed to provide an independent replication of this phenotype in first-degree relatives of SCZ patients. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Recently, clinical guidelines about treatment of mania have been published by important scientific societies.1 Atypical antipsychotic adjunctive therapy to lithium or valproate is effective in treating acute mania; however, antipsychotics should not be continued unless the benefits of reducing relapse outweigh the risks such as weight gain and metabolic syndrome.2 So far, there is no high-quality evidence for such beneficial duration of the therapy. The study by Yatham and colleagues aimed to determine the efficacy of different durations (24 and 52 weeks) of atypical antipsychotic adjunctive therapy to mood stabiliser versus discontinuing …..To read the full article, log in using your NHS OpenAthens details.
Armodafinil (Nuvigil®) is an eugeroic drug made by Cephalon, FDA-approved 6/15/2007. Clinical trials for its use in bipolar disorder, cognition in schizophrenia, excessive fatigue in Parkinson's & cancer, begin. Patent expires 2023.
It is important that nurses who work with individuals experiencing Serious Mental Illness (SMI) understand the assessment and management of specific communication, speech and language needs. You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Do 7-year-old children at familial high risk of schizophrenia spectrum disorders or bipolar disorder have neurocognitive impairments, and how do their neurocognitive profiles differ?. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Studies involving clinically recruited samples show that genetic liability to schizophrenia overlaps with that for several psychiatric disorders including bipolar disorder, major depression and, in a population study, anxiety disorder and negative symptoms in adolescence.. To read the full article, log in using your MPFT NHS OpenAthens details.
People with severe mental illnesses (SMI) such as schizophrenia and bipolar disorder have an increased risk of developing type 2 diabetes and have poorer health outcomes than those with diabetes alone. To maintain good diabetes control, people with diabetes are advised to engage in several self-management behaviours. The aim of this study was to identify barriers or enablers of diabetes self-management experienced by people with SMI.
Open access journal. Basic symptoms, defined as subjectively perceived disturbances in thought, perception and other essential mental processes, have been established as a predictor of psychotic disorders. However, the relationship between basic symptoms and family history of a transdiagnostic range of severe mental illness, including major depressive disorder, bipolar disorder and schizophrenia, has not been examined.
We’ve just heard that SSOTP will not be renewing their agreement with SSSFT LKS for library services for this financial year. Because of this we will be reviewing our Be Aware bulletins. Sadly we won’t be accepting any new sign-ups from SSOTP staff and will be withdrawing some of the physical healthcare bulletins that we…
We're currently making some changes in the background of our email updates to solve some problems we've been having recently. During our testing phase this may automatically generate some alerts, which will show below, but you can ignore these! If all goes according to plan we will be resuming normal service in the next week…
Smoking in the general population is on the decline. However, in people with severe mental disorders (SMDs) such as schizophrenia and bipolar disorder the estimated smoking prevalence rate is anywhere between 50-80%. High rates of medical morbidity and severely reduced life expectancy are associated with increased prevalence rates in these individuals.
Pharmacological treatments for smoking cessation are effective in the general population. We have blogged extensively about the efficacy, tolerability and cost-effectiveness of the three main treatments; transdermal nicotine patches (TNP), varenicline and bupropion.
There is emerging evidence to suggest individuals with SMDs are often motivated to quit and pharmacological treatments in those with SMDs are similarly effective. Despite these promising findings, treatments are often under-utilised, with one study finding less than one third of clinicians advising patients about smoking cessation.
While CVD risk has decreased in the general population during the last decade, the situation in patients with schizophrenia (SCZ) and bipolar disorder (BD) is unknown.. To read the full article, log in using your NHS Athens details. To access full-text: click “Log in/Register” (top right hand side). Click ‘Institutional Login’ then select 'OpenAthens Federation', then ‘NHS England’. Enter your Athens details to view the article.